| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis B virus | 73 | 2024 | 155 | 17.480 |
Why?
|
| Hepatitis B | 58 | 2024 | 123 | 14.400 |
Why?
|
| Liver Neoplasms | 21 | 2024 | 59 | 7.690 |
Why?
|
| Carcinoma, Hepatocellular | 19 | 2024 | 51 | 6.800 |
Why?
|
| Hepatitis B, Chronic | 16 | 2023 | 44 | 6.400 |
Why?
|
| DNA, Viral | 39 | 2023 | 165 | 4.750 |
Why?
|
| Genotype | 41 | 2024 | 430 | 4.670 |
Why?
|
| Hepatitis B e Antigens | 20 | 2023 | 26 | 3.940 |
Why?
|
| Genome, Viral | 21 | 2020 | 64 | 3.760 |
Why?
|
| Hepatitis B Surface Antigens | 19 | 2021 | 47 | 2.740 |
Why?
|
| Phylogeny | 32 | 2022 | 231 | 2.520 |
Why?
|
| Mutation | 21 | 2023 | 299 | 2.390 |
Why?
|
| Humans | 87 | 2024 | 14077 | 2.350 |
Why?
|
| MicroRNAs | 5 | 2021 | 32 | 2.250 |
Why?
|
| Coinfection | 7 | 2018 | 268 | 1.900 |
Why?
|
| Hepatitis B Core Antigens | 8 | 2021 | 10 | 1.840 |
Why?
|
| Promoter Regions, Genetic | 11 | 2021 | 36 | 1.580 |
Why?
|
| Trans-Activators | 4 | 2021 | 22 | 1.500 |
Why?
|
| Sequence Analysis, DNA | 12 | 2018 | 180 | 1.490 |
Why?
|
| Viral Regulatory and Accessory Proteins | 4 | 2021 | 26 | 1.480 |
Why?
|
| Antiviral Agents | 10 | 2023 | 107 | 1.470 |
Why?
|
| Computational Biology | 4 | 2015 | 43 | 1.420 |
Why?
|
| Hepatitis C | 6 | 2022 | 37 | 1.290 |
Why?
|
| Adult | 33 | 2023 | 5664 | 1.230 |
Why?
|
| Male | 35 | 2023 | 6489 | 1.180 |
Why?
|
| HIV Infections | 11 | 2022 | 4946 | 1.160 |
Why?
|
| Virus Replication | 8 | 2024 | 87 | 1.140 |
Why?
|
| Liver Cirrhosis | 5 | 2017 | 27 | 1.140 |
Why?
|
| Unfolded Protein Response | 2 | 2017 | 2 | 1.120 |
Why?
|
| Female | 35 | 2023 | 8751 | 1.010 |
Why?
|
| Protein Precursors | 8 | 2013 | 22 | 1.010 |
Why?
|
| Proteomics | 1 | 2024 | 13 | 0.930 |
Why?
|
| Sequence Alignment | 7 | 2020 | 59 | 0.880 |
Why?
|
| Genetic Variation | 9 | 2020 | 169 | 0.840 |
Why?
|
| Middle Aged | 18 | 2020 | 3425 | 0.830 |
Why?
|
| Kidney Failure, Chronic | 1 | 2022 | 25 | 0.820 |
Why?
|
| Hepatitis C, Chronic | 1 | 2022 | 26 | 0.820 |
Why?
|
| Host-Pathogen Interactions | 3 | 2024 | 24 | 0.820 |
Why?
|
| Viral Core Proteins | 6 | 2014 | 10 | 0.810 |
Why?
|
| Cross Infection | 1 | 2022 | 49 | 0.810 |
Why?
|
| Base Sequence | 17 | 2014 | 149 | 0.810 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 3 | 0.800 |
Why?
|
| Liver | 8 | 2021 | 74 | 0.800 |
Why?
|
| Molecular Sequence Data | 19 | 2014 | 263 | 0.790 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 17 | 0.750 |
Why?
|
| Open Reading Frames | 7 | 2011 | 16 | 0.740 |
Why?
|
| Developing Countries | 1 | 2024 | 385 | 0.740 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2023 | 247 | 0.730 |
Why?
|
| Carrier State | 10 | 2013 | 89 | 0.720 |
Why?
|
| Africa South of the Sahara | 7 | 2024 | 328 | 0.710 |
Why?
|
| Hepatitis B Vaccines | 4 | 2023 | 38 | 0.710 |
Why?
|
| Viral Load | 9 | 2020 | 808 | 0.700 |
Why?
|
| Transfection | 6 | 2024 | 29 | 0.650 |
Why?
|
| South Africa | 18 | 2023 | 7312 | 0.640 |
Why?
|
| Hepatocytes | 6 | 2020 | 19 | 0.630 |
Why?
|
| Lamivudine | 1 | 2018 | 86 | 0.620 |
Why?
|
| Cell Line | 6 | 2021 | 92 | 0.580 |
Why?
|
| Mutant Proteins | 1 | 2017 | 3 | 0.580 |
Why?
|
| Young Adult | 6 | 2023 | 2357 | 0.570 |
Why?
|
| Cell Line, Tumor | 3 | 2024 | 70 | 0.550 |
Why?
|
| Child | 14 | 2023 | 2180 | 0.510 |
Why?
|
| Hepadnaviridae | 2 | 2010 | 2 | 0.500 |
Why?
|
| Adolescent | 17 | 2023 | 2858 | 0.500 |
Why?
|
| Glomerulonephritis, Membranous | 5 | 2010 | 5 | 0.500 |
Why?
|
| Phylogeography | 5 | 2020 | 15 | 0.490 |
Why?
|
| Anti-Retroviral Agents | 2 | 2018 | 542 | 0.490 |
Why?
|
| Virology | 5 | 2018 | 13 | 0.480 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 1377 | 0.470 |
Why?
|
| Amino Acid Sequence | 6 | 2010 | 139 | 0.470 |
Why?
|
| Genomics | 1 | 2015 | 106 | 0.460 |
Why?
|
| Point Mutation | 3 | 2011 | 16 | 0.440 |
Why?
|
| Sudan | 3 | 2022 | 9 | 0.440 |
Why?
|
| Human Migration | 1 | 2013 | 8 | 0.430 |
Why?
|
| Immunization Programs | 2 | 2012 | 78 | 0.430 |
Why?
|
| Prevalence | 8 | 2016 | 1149 | 0.430 |
Why?
|
| Papio ursinus | 1 | 2013 | 3 | 0.430 |
Why?
|
| Online Systems | 1 | 2013 | 2 | 0.430 |
Why?
|
| Animals | 15 | 2021 | 1063 | 0.410 |
Why?
|
| Protein Biosynthesis | 2 | 2011 | 8 | 0.400 |
Why?
|
| Interferon-alpha | 2 | 2010 | 15 | 0.390 |
Why?
|
| Transfusion Reaction | 1 | 2011 | 1 | 0.390 |
Why?
|
| Treatment Outcome | 4 | 2022 | 867 | 0.380 |
Why?
|
| Blood Donors | 2 | 2011 | 19 | 0.380 |
Why?
|
| Disease Progression | 4 | 2022 | 154 | 0.380 |
Why?
|
| Molecular Epidemiology | 3 | 2018 | 44 | 0.370 |
Why?
|
| Case-Control Studies | 6 | 2020 | 464 | 0.360 |
Why?
|
| Aged | 8 | 2018 | 1650 | 0.360 |
Why?
|
| Home Childbirth | 1 | 2010 | 5 | 0.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 20 | 0.360 |
Why?
|
| Hepatitis B Antibodies | 4 | 2020 | 10 | 0.350 |
Why?
|
| Africa | 4 | 2018 | 360 | 0.350 |
Why?
|
| Orthohepadnavirus | 1 | 2010 | 1 | 0.350 |
Why?
|
| Conserved Sequence | 1 | 2010 | 10 | 0.340 |
Why?
|
| Internet | 3 | 2015 | 12 | 0.340 |
Why?
|
| Disease Models, Animal | 6 | 2021 | 45 | 0.330 |
Why?
|
| Hepacivirus | 3 | 2022 | 37 | 0.320 |
Why?
|
| HIV-1 | 2 | 2017 | 1239 | 0.310 |
Why?
|
| In Vitro Techniques | 2 | 2020 | 54 | 0.310 |
Why?
|
| Retrospective Studies | 3 | 2020 | 767 | 0.290 |
Why?
|
| Biomarkers | 2 | 2022 | 322 | 0.280 |
Why?
|
| Apoptosis | 2 | 2017 | 39 | 0.280 |
Why?
|
| Vaccination | 2 | 2023 | 347 | 0.270 |
Why?
|
| Child, Preschool | 8 | 2022 | 1675 | 0.270 |
Why?
|
| Cohort Studies | 3 | 2018 | 939 | 0.260 |
Why?
|
| Genetic Heterogeneity | 1 | 2005 | 8 | 0.250 |
Why?
|
| Viremia | 2 | 2014 | 66 | 0.250 |
Why?
|
| Virus Diseases | 2 | 2023 | 55 | 0.240 |
Why?
|
| Cloning, Molecular | 4 | 2014 | 26 | 0.240 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2019 | 11 | 0.240 |
Why?
|
| rhoC GTP-Binding Protein | 1 | 2024 | 1 | 0.240 |
Why?
|
| Proteome | 1 | 2024 | 4 | 0.230 |
Why?
|
| Hepatitis Delta Virus | 1 | 2024 | 1 | 0.230 |
Why?
|
| Signal Transduction | 1 | 2024 | 33 | 0.230 |
Why?
|
| Policy | 1 | 2023 | 42 | 0.210 |
Why?
|
| Plasmids | 2 | 2014 | 23 | 0.210 |
Why?
|
| Genotyping Techniques | 2 | 2013 | 38 | 0.210 |
Why?
|
| Universities | 1 | 2023 | 34 | 0.210 |
Why?
|
| Students | 1 | 2023 | 48 | 0.210 |
Why?
|
| Renal Dialysis | 1 | 2022 | 25 | 0.210 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 104 | 0.200 |
Why?
|
| Evolution, Molecular | 3 | 2014 | 60 | 0.200 |
Why?
|
| Risk Factors | 3 | 2018 | 1431 | 0.200 |
Why?
|
| Dependovirus | 1 | 2021 | 8 | 0.200 |
Why?
|
| Hepatitis B Antigens | 3 | 2014 | 6 | 0.200 |
Why?
|
| Cell Nucleus | 1 | 2021 | 3 | 0.190 |
Why?
|
| Protein Transport | 1 | 2021 | 7 | 0.190 |
Why?
|
| Hep G2 Cells | 1 | 2021 | 14 | 0.190 |
Why?
|
| Cytoplasm | 1 | 2021 | 7 | 0.190 |
Why?
|
| Polymorphism, Restriction Fragment Length | 4 | 2011 | 20 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 8 | 2005 | 260 | 0.180 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 46 | 0.180 |
Why?
|
| Likelihood Functions | 1 | 2020 | 3 | 0.180 |
Why?
|
| Africa, Western | 1 | 2020 | 6 | 0.180 |
Why?
|
| Databases, Genetic | 1 | 2020 | 20 | 0.180 |
Why?
|
| Software | 2 | 2013 | 36 | 0.180 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 41 | 0.180 |
Why?
|
| Virus Physiological Phenomena | 1 | 2020 | 1 | 0.180 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2020 | 1 | 0.180 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 4 | 0.180 |
Why?
|
| Cell Differentiation | 1 | 2020 | 20 | 0.170 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 7 | 0.170 |
Why?
|
| Drug Resistance, Viral | 1 | 2022 | 268 | 0.170 |
Why?
|
| Pandemics | 1 | 2022 | 280 | 0.170 |
Why?
|
| Sequence Deletion | 3 | 2016 | 16 | 0.170 |
Why?
|
| DNA Primers | 4 | 2012 | 55 | 0.160 |
Why?
|
| Virus Assembly | 1 | 1998 | 1 | 0.160 |
Why?
|
| Gene Expression | 2 | 2021 | 43 | 0.150 |
Why?
|
| Circulating MicroRNA | 1 | 2017 | 1 | 0.150 |
Why?
|
| Antibodies, Viral | 2 | 2012 | 266 | 0.150 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 25 | 0.150 |
Why?
|
| Pediatrics | 1 | 2018 | 16 | 0.150 |
Why?
|
| Epidemics | 1 | 2018 | 64 | 0.150 |
Why?
|
| Geography | 2 | 2014 | 60 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 42 | 0.140 |
Why?
|
| Endoplasmic Reticulum | 1 | 2017 | 2 | 0.140 |
Why?
|
| Protein Sorting Signals | 1 | 2017 | 2 | 0.140 |
Why?
|
| Mutation, Missense | 1 | 2017 | 65 | 0.140 |
Why?
|
| Proteinuria | 3 | 2002 | 14 | 0.140 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2016 | 1 | 0.140 |
Why?
|
| Secretory Pathway | 1 | 2016 | 1 | 0.140 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2016 | 1 | 0.140 |
Why?
|
| Cercopithecus | 2 | 1987 | 2 | 0.130 |
Why?
|
| Bone Marrow Cells | 2 | 1987 | 5 | 0.130 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2020 | 467 | 0.130 |
Why?
|
| India | 2 | 2013 | 60 | 0.130 |
Why?
|
| Incidence | 1 | 2018 | 655 | 0.130 |
Why?
|
| Cytomegalovirus | 2 | 2023 | 24 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2012 | 150 | 0.130 |
Why?
|
| Hepatitis C Antibodies | 1 | 2014 | 3 | 0.120 |
Why?
|
| Phenotype | 2 | 2013 | 144 | 0.120 |
Why?
|
| Pregnancy | 1 | 2020 | 1815 | 0.120 |
Why?
|
| Algorithms | 1 | 2015 | 105 | 0.120 |
Why?
|
| Infant, Newborn | 3 | 2023 | 1410 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 47 | 0.110 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 45 | 0.110 |
Why?
|
| Age of Onset | 1 | 2013 | 32 | 0.110 |
Why?
|
| Acute Disease | 2 | 2011 | 105 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2013 | 132 | 0.110 |
Why?
|
| Anti-HIV Agents | 2 | 2012 | 1275 | 0.110 |
Why?
|
| Time Factors | 2 | 2012 | 503 | 0.110 |
Why?
|
| Databases, Nucleic Acid | 1 | 2013 | 3 | 0.110 |
Why?
|
| Papio | 3 | 2003 | 28 | 0.110 |
Why?
|
| Asymptomatic Infections | 1 | 2013 | 29 | 0.110 |
Why?
|
| Molecular Typing | 1 | 2013 | 12 | 0.110 |
Why?
|
| Bayes Theorem | 1 | 2013 | 77 | 0.110 |
Why?
|
| Kenya | 1 | 2013 | 173 | 0.110 |
Why?
|
| Aspartate Aminotransferases | 1 | 2012 | 10 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 38 | 0.100 |
Why?
|
| Serologic Tests | 1 | 2012 | 26 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 90 | 0.100 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 9 | 0.100 |
Why?
|
| Fluorescence | 1 | 2011 | 9 | 0.100 |
Why?
|
| Genes, Reporter | 1 | 2011 | 12 | 0.100 |
Why?
|
| Sex Factors | 1 | 2012 | 224 | 0.100 |
Why?
|
| Codon, Nonsense | 1 | 2011 | 1 | 0.100 |
Why?
|
| Mutagenesis, Insertional | 1 | 2011 | 8 | 0.100 |
Why?
|
| Recombinant Proteins | 2 | 2010 | 72 | 0.100 |
Why?
|
| Prognosis | 2 | 2017 | 197 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 34 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2011 | 65 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2011 | 64 | 0.100 |
Why?
|
| Risk | 1 | 2011 | 87 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 96 | 0.090 |
Why?
|
| Bone Marrow | 2 | 1987 | 19 | 0.090 |
Why?
|
| Zimbabwe | 1 | 2011 | 115 | 0.090 |
Why?
|
| Genetic Markers | 1 | 2010 | 11 | 0.090 |
Why?
|
| World Health Organization | 1 | 2010 | 134 | 0.090 |
Why?
|
| Treatment Failure | 1 | 2010 | 175 | 0.080 |
Why?
|
| Disease Eradication | 2 | 2019 | 11 | 0.080 |
Why?
|
| Mice | 3 | 2021 | 134 | 0.080 |
Why?
|
| Rural Population | 1 | 2012 | 624 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2005 | 1 | 0.060 |
Why?
|
| Virus Integration | 1 | 2005 | 2 | 0.060 |
Why?
|
| Madagascar | 1 | 2005 | 3 | 0.060 |
Why?
|
| Africa, Southern | 1 | 2005 | 89 | 0.060 |
Why?
|
| RNA, Viral | 3 | 2004 | 303 | 0.060 |
Why?
|
| Health Policy | 2 | 2018 | 132 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2017 | 654 | 0.060 |
Why?
|
| Japan | 1 | 2024 | 7 | 0.060 |
Why?
|
| Hepatitis D | 1 | 2024 | 4 | 0.060 |
Why?
|
| Brazil | 2 | 2014 | 43 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2024 | 7 | 0.060 |
Why?
|
| Hepatitis B Virus, Duck | 1 | 2004 | 1 | 0.060 |
Why?
|
| Ducks | 1 | 2004 | 3 | 0.060 |
Why?
|
| Codon, Initiator | 1 | 2003 | 1 | 0.060 |
Why?
|
| Greece | 1 | 2023 | 2 | 0.060 |
Why?
|
| Oligonucleotide Probes | 1 | 2003 | 6 | 0.050 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2003 | 5 | 0.050 |
Why?
|
| Aflatoxin B1 | 1 | 2022 | 2 | 0.050 |
Why?
|
| HLA-DQ Antigens | 1 | 2002 | 8 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2002 | 38 | 0.050 |
Why?
|
| Infant | 3 | 2022 | 2145 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2021 | 20 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2021 | 54 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2004 | 380 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2020 | 10 | 0.040 |
Why?
|
| Amino Acid Substitution | 2 | 2014 | 35 | 0.040 |
Why?
|
| Epitopes | 1 | 2020 | 97 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 2019 | 6 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 6 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2019 | 7 | 0.040 |
Why?
|
| Forecasting | 1 | 2019 | 20 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 25 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 33 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 59 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2017 | 1131 | 0.040 |
Why?
|
| Research | 1 | 2019 | 65 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 53 | 0.040 |
Why?
|
| Thymine | 1 | 1998 | 1 | 0.040 |
Why?
|
| Codon, Terminator | 1 | 1998 | 3 | 0.040 |
Why?
|
| Guanine | 1 | 1998 | 3 | 0.040 |
Why?
|
| Global Health | 1 | 2019 | 183 | 0.040 |
Why?
|
| ROC Curve | 1 | 2017 | 47 | 0.040 |
Why?
|
| Nigeria | 1 | 2017 | 40 | 0.040 |
Why?
|
| Cytopathogenic Effect, Viral | 2 | 2006 | 4 | 0.040 |
Why?
|
| Chloroform | 1 | 1996 | 1 | 0.030 |
Why?
|
| Phenol | 1 | 1996 | 4 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 1996 | 4 | 0.030 |
Why?
|
| Phenols | 1 | 1996 | 4 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 25 | 0.030 |
Why?
|
| China | 1 | 2016 | 21 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 367 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2006 | 12 | 0.030 |
Why?
|
| Clone Cells | 2 | 1987 | 4 | 0.030 |
Why?
|
| Alanine Transaminase | 2 | 2009 | 23 | 0.030 |
Why?
|
| Cell Division | 2 | 1987 | 12 | 0.030 |
Why?
|
| Cell Adhesion | 2 | 1987 | 18 | 0.030 |
Why?
|
| Fibroblasts | 2 | 1987 | 14 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 312 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2014 | 7 | 0.030 |
Why?
|
| Asia | 1 | 2014 | 70 | 0.030 |
Why?
|
| Transplantation, Heterologous | 2 | 2006 | 9 | 0.030 |
Why?
|
| HIV | 1 | 2017 | 380 | 0.030 |
Why?
|
| Immunization Schedule | 1 | 2012 | 70 | 0.020 |
Why?
|
| DNA Fingerprinting | 1 | 2009 | 9 | 0.020 |
Why?
|
| Sequence Homology | 1 | 2009 | 11 | 0.020 |
Why?
|
| Serotyping | 1 | 2009 | 63 | 0.020 |
Why?
|
| Vietnam | 1 | 2008 | 11 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 1987 | 4 | 0.020 |
Why?
|
| Cell Cycle | 1 | 1987 | 4 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1987 | 6 | 0.020 |
Why?
|
| Kinetics | 1 | 1987 | 65 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 1987 | 79 | 0.020 |
Why?
|
| DNA | 1 | 1987 | 73 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 1987 | 23 | 0.020 |
Why?
|
| Chimera | 1 | 2006 | 3 | 0.020 |
Why?
|
| Culture Media | 1 | 2006 | 15 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2006 | 32 | 0.020 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2006 | 1 | 0.020 |
Why?
|
| Transplantation Chimera | 1 | 2006 | 1 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2006 | 4 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2006 | 53 | 0.020 |
Why?
|
| Genes, Regulator | 1 | 2004 | 1 | 0.010 |
Why?
|
| Hepatitis, Viral, Animal | 1 | 2004 | 1 | 0.010 |
Why?
|
| Hepadnaviridae Infections | 1 | 2004 | 1 | 0.010 |
Why?
|
| Nucleic Acid Conformation | 1 | 2004 | 7 | 0.010 |
Why?
|
| Poultry Diseases | 1 | 2004 | 3 | 0.010 |
Why?
|
| Biotin | 1 | 2003 | 2 | 0.010 |
Why?
|
| Species Specificity | 1 | 2003 | 49 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2004 | 190 | 0.010 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2002 | 2 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 27 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2002 | 7 | 0.010 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2002 | 6 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 77 | 0.010 |
Why?
|
| Kidney | 1 | 2002 | 46 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 2001 | 4 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2001 | 27 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2001 | 6 | 0.010 |
Why?
|
| Disease Transmission, Infectious | 1 | 2001 | 39 | 0.010 |
Why?
|
| Hepatitis Antibodies | 1 | 2000 | 1 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2000 | 5 | 0.010 |
Why?
|
| Transaminases | 1 | 2000 | 5 | 0.010 |
Why?
|
| Virion | 1 | 2000 | 12 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2001 | 100 | 0.010 |
Why?
|
| Family | 1 | 1999 | 33 | 0.010 |
Why?
|
| Creatinine | 1 | 1999 | 51 | 0.010 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1999 | 4 | 0.010 |
Why?
|
| Heterozygote | 1 | 1999 | 42 | 0.010 |
Why?
|
| Contact Tracing | 1 | 1999 | 47 | 0.010 |
Why?
|
| Gene Frequency | 1 | 1999 | 117 | 0.010 |
Why?
|